Latest Methylphenidate Stories
BOCA RATON, Fla., July 28 /PRNewswire/ -- Breckenridge announced today that through its agreement with Tris Pharma, the company will market Methylphenidate Solution, the generic version of MethylinÂ® marketed by Shionogi Pharma, Inc., under an Abbreviated New Drug Application (ANDA).
MONMOUTH JUNCTION, N.J., July 28 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced that the US Food and Drug Administration (FDA) has approved a first-time generic of Methylphenidate Hydrochloride Oral Solution equivalent to brand name MethylinÂ® Oral Solution marketed by Shionogi Pharmaceuticals, Inc. "Tris pursues selective generic opportunities, especially the difficult to formulate or complex formulations and...
DUBLIN and PHILADELPHIA, July 6 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of DaytranaÂ® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years.
A new study shows that use of psychotropic medications during pregnancy increase the probability of birth defects.
Between 1998 and 2007, psychotropic medications were associated with 429 adverse drug reactions (ADRs) in children under 17 in Denmark.
A new study published online in the Journal of Pediatrics suggests that neither attention deficit hyperactivity disorder (ADHD) nor medications used to treat it have a long-term impact on kids' growth.
Cancer-related fatigue is often a major problem for cancer patients, beginning at diagnosis, during treatment and after completing therapy.
NEW ORLEANS, May 25 /PRNewswire/ -- Turning in assignments, following instructions and focusing on learning something new are among the daily classroom challenges for children with Attention Deficit Hyperactivity Disorder (ADHD),(1) according to the National Institute of Mental Health (NIMH).
PHILADELPHIA, May 19 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, will present scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments VyvanseÂ® (lisdexamfetamine dimesylate) Capsules CII and INTUNIV(TM) (guanfacine) Extended Release Tablets at two national scientific meetings for psychiatrists May 20-26, 2010 in New Orleans, LA.
Several barriers prevent minority children with ADHD from receiving the most effective treatments, according to a new study by Michigan State University researchers.
- totally perplexed and mixed up.